Novo Nordisk AS (BSP:N1VO34) EPS (Basic) : R$2.03 (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Novo Nordisk AS EPS (Basic)?

Novo Nordisk AS's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was R$0.63. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was R$2.03.

Novo Nordisk AS's EPS (Diluted) for the three months ended in Sep. 2024 was R$0.63. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was R$2.02.

Novo Nordisk AS's EPS without NRI for the three months ended in Sep. 2024 was R$0.63. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was 2.02.

During the past 12 months, Novo Nordisk AS's average EPS without NRIGrowth Rate was 26.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 26.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 17.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 11.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Novo Nordisk AS's highest 3-Year average EPS without NRI Growth Rate was 38.20% per year. The lowest was -2.90% per year. And the median was 18.60% per year.

Novo Nordisk AS EPS (Basic) Historical Data

The historical data trend for Novo Nordisk AS's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS EPS (Basic) Chart

Novo Nordisk AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

0.63

0.95

1.12

1.15

1.67

Novo Nordisk AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															0.44	0.44	0.52	0.44	0.63

Novo Nordisk AS EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Novo Nordisk AS's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(59991.509	-	0)	/	35862.400
	=	1.67

Novo Nordisk AS's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(22504.834	-	0)	/	35618.400
	=	0.63

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$2.03

Novo Nordisk AS (BSP:N1VO34) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Novo Nordisk AS EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (BSP:N1VO34) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines